These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 26613572)

  • 1. Cost effectiveness of a systematic guidelines-based approach to the prevention and management of vascular disease in a primary care setting.
    Kamboj L; Oh P; Levine M; Kammila S; Casey W; Harterre D; Goeree R
    Int J Cardiol; 2016 Jan; 203():893-9. PubMed ID: 26613572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
    Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
    Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
    Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
    Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
    Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
    Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
    Tunis SL
    Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania.
    Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R
    Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of elective endovascular repair compared with open surgical repair of abdominal aortic aneurysms for patients at a high surgical risk: A 1-year patient-level analysis conducted in Ontario, Canada.
    Tarride JE; Blackhouse G; De Rose G; Novick T; Bowen JM; Hopkins R; O'Reilly D; Goeree R
    J Vasc Surg; 2008 Oct; 48(4):779-87. PubMed ID: 18639421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases.
    Corrao G; Scotti L; Zambon A; Baio G; Nicotra F; Conti V; Capri S; Tragni E; Merlino L; Catapano AL; Mancia G
    Atherosclerosis; 2011 Aug; 217(2):479-85. PubMed ID: 21592477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences.
    Huybrechts KF; Caro JJ; O'Brien JA
    Value Health; 2009; 12(1):16-9. PubMed ID: 18647261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carotid ultrasound identifies high risk subclinical atherosclerosis in adults with low framingham risk scores.
    Eleid MF; Lester SJ; Wiedenbeck TL; Patel SD; Appleton CP; Nelson MR; Humphries J; Hurst RT
    J Am Soc Echocardiogr; 2010 Aug; 23(8):802-8. PubMed ID: 20591621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
    Wielage RC; Bansal M; Andrews JS; Klein RW; Happich M
    Appl Health Econ Health Policy; 2013 Jun; 11(3):219-36. PubMed ID: 23616247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial.
    Ohsfeldt RL; Olsson AG; Jensen MM; Gandhi SK; Paulsson T
    J Med Econ; 2012; 15(1):125-33. PubMed ID: 22050473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of transcatheter aortic valve replacement compared to medical management in inoperable patients with severe aortic stenosis: Canadian analysis based on the PARTNER Trial Cohort B findings.
    Hancock-Howard RL; Feindel CM; Rodes-Cabau J; Webb JG; Thompson AK; Banz K
    J Med Econ; 2013; 16(4):566-74. PubMed ID: 23356420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model.
    Cipriano LE; Rupar CA; Zaric GS
    Value Health; 2007; 10(2):83-97. PubMed ID: 17391418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of a falls prevention exercise program among people With Parkinson's disease.
    Farag I; Sherrington C; Hayes A; Canning CG; Lord SR; Close JC; Fung VS; Howard K
    Mov Disord; 2016 Jan; 31(1):53-61. PubMed ID: 26395438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of a treatment advice to discontinue inappropriate long-term antidepressant use in primary care.
    Eveleigh R; Grutters J; Muskens E; Oude Voshaar R; van Weel C; Speckens A; Lucassen P
    Fam Pract; 2014 Oct; 31(5):578-84. PubMed ID: 25121977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
    Ribeiro RA; Duncan BB; Ziegelmann PK; Stella SF; Vieira JL; Restelatto LM; Polanczyk CA
    Arq Bras Cardiol; 2015 Jan; 104(1):32-44. PubMed ID: 25409878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective.
    Osnabrugge RL; Magnuson EA; Serruys PW; Campos CM; Wang K; van Klaveren D; Farooq V; Abdallah MS; Li H; Vilain KA; Steyerberg EW; Morice MC; Dawkins KD; Mohr FW; Kappetein AP; Cohen DJ;
    Heart; 2015 Dec; 101(24):1980-8. PubMed ID: 26552756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.